NCT00004203: Oxaliplatin in Treating Patients With Metastatic Bladder Cancer |
|
|
| Completed | 2 | 20 | US, Canada | oxaliplatin | University of Chicago, National Cancer Institute (NCI) | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | 02/02 | 04/05 | | |
NCT00186277: Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer |
|
|
| Completed | 2 | 10 | US | Oxaliplatin, Eloxatin, Taxotere, Docetaxel | Stanford University, Sanofi-Synthelabo | Bladder Cancer | 12/06 | 12/06 | | |
NCT00627432: Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer |
|
|
| Suspended | 2 | 100 | Europe | gemcitabine hydrochloride, oxaliplatin | Institut du Cancer de Montpellier - Val d'Aurelle | Bladder Cancer | 03/09 | | | |
CORGI, NCT01016639: Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer |
|
|
| Completed | 1/2 | 106 | Europe | oxaliplatin, capecitabine, radiotherapy | Lund University Hospital, Roche Pharma AG, Sanofi-Synthelabo | Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer, Colorectal Cancer | 07/07 | 07/09 | | |
